Your browser doesn't support javascript.
loading
Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children.
Duncan, Jennifer C; Bracken, Louise E; Nunn, Anthony J; Peak, Matthew; Turner, Mark A.
Afiliação
  • Duncan JC; Paediatric Medicines Research Unit, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. Jennifer.Duncan@alderhey.nhs.uk.
  • Bracken LE; Paediatric Medicines Research Unit, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
  • Nunn AJ; Paediatric Medicines Research Unit, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
  • Peak M; Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Health Partners, Liverpool, UK.
  • Turner MA; Paediatric Medicines Research Unit, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Int J Clin Pharm ; 44(6): 1394-1405, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36208398
ABSTRACT

BACKGROUND:

Medicines designed for adults may be inappropriate for use in children in terms of strength, dosage form and/or excipient content. There is currently no standardised method of assessing the age-appropriateness of a medicine for paediatric use.

AIM:

To develop and test a tool to assess whether a dosage form (formulation) is appropriate for children and estimate the proportion of formulations considered 'inappropriate' in a cohort of hospitalised paediatric patients with a chronic illness.

METHOD:

A multi-phase study patient data collection, tool development, case assessments and tool validation. Inpatients aged 0-17 years at two UK paediatric/neonatal hospitals during data collection periods between January 2015 and March 2016. Written informed consent/assent was obtained. Medicines assessed were new or regularly prescribed to inpatients as part of their routine clinical care. All medicine administration episodes recorded were assessed using the Age-appropriate Formulation tool. The tool was developed by a consensus approach, as a one-page flowchart. Independent case assessments were evaluated in 2019.

RESULTS:

In 427 eligible children; 2,199 medicine administration episodes were recorded. Two assessors reviewed 220 episodes in parallel percentage exact agreement was found to be 91.7% (99/108) and 93.1% (95/102). In total, 259/2,199 (11.8%) medicine administration episodes involved a dosage form categorised as 'age-inappropriate'.

CONCLUSION:

A novel tool has been developed and internally validated. The tool can identify which medicines would benefit from development of an improved paediatric formulation. It has shown high inter-rater reliability between users. External validation is needed to further assess the tool's utility in different settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Excipientes / Hospitais Pediátricos Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans / Newborn Idioma: En Revista: Int J Clin Pharm Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Excipientes / Hospitais Pediátricos Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans / Newborn Idioma: En Revista: Int J Clin Pharm Ano de publicação: 2022 Tipo de documento: Article